Sipuleucel-T: Prototype for Development of Anti-tumor Vaccines

被引:0
|
作者
Estrella Carballido
Mayer Fishman
机构
[1] Moffitt Cancer Center and Research Institute,
来源
Current Oncology Reports | 2011年 / 13卷
关键词
Dendritic cell vaccine; Vaccines; Immunotherapy; Prostate cancer; PAP-GM-CSF fusion protein;
D O I
暂无
中图分类号
学科分类号
摘要
Prostate cancer immunotherapy officially debuted with the recent FDA approval of Sipuleucel-T. The novel trend of cancer immunotherapy relies on the identification of particular tumor-associated antigens, like prostatic acid phosphatase (PAP). Sipuleucel-T consists of autologous dendritic cells activated in vitro with recombinant fusion protein PA2024, PAP-linked to granulocyte-macrophage colony-stimulating factor. Sipuleucel-T represents a prototype for the development of cancer vaccines. Preclinical and clinical data as well as landmark studies for the existing narrow chemotherapy alternatives and early immunotherapy trials will be discussed. The pivotal trial demonstrated a 4.1-month difference of median survival, but with no effect on time to progression in asymptomatic or minimally symptomatic metastatic castrate-resistant patients. Several immunologic effects were observed in the treated population, including antibody and T cell–specific activity to P2024 and PAP. With all new therapies the extent of clinical and objective benefits versus encountered limitations should be evaluated. This review highlights the events and decisions in the process of the development of Sipuleucel-T. We discuss how this successful immunotherapy outcome challenges us to use it as a starting point for variations to or try to amplify practical anticancer progress within the antitumor vaccine paradigm.
引用
收藏
页码:112 / 119
页数:7
相关论文
共 50 条
  • [41] What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence
    Hu, Rachel
    George, Daniel J.
    Zhang, Tian
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (04) : 272 - 278
  • [42] Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T
    McNamara, Megan
    Berry, William
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : E361 - E364
  • [43] Anti-tumor Vaccines in head and neck cancer: Targeting immune responses to the tumor
    Whiteside, Theresa L.
    CURRENT CANCER DRUG TARGETS, 2007, 7 (07) : 633 - 642
  • [44] Sipuleucel-T in Metastatic Castration-Resistant Prostate Concert Profile Report
    Plosker, Greg L.
    BIODRUGS, 2011, 25 (04) : 255 - 256
  • [45] Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
    Caram, Megan E. V.
    Ross, Ryan
    Lin, Paul
    Mukherjee, Bhramar
    JAMA NETWORK OPEN, 2019, 2 (04)
  • [46] Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
    GuhaThakurta, Debraj
    Sheikh, Nadeem A.
    Fan, Li-Qun
    Kandadi, Harini
    Meagher, T. Craig
    Hall, Simon J.
    Kantoff, Philip W.
    Higano, Celestia S.
    Small, Eric J.
    Gardner, Thomas A.
    Bailey, Kate
    Vu, Tuyen
    DeVries, Todd
    Whitmore, James B.
    Frohlich, Mark W.
    Trager, James B.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3619 - 3630
  • [47] Preoperative Sipuleucel-T Results in Tumor Lymphocyte Infiltration in Prostate Cancer Specimens: Evidence of Immune Activation and Response Within The Prostate Tumor Microenvironment
    Fong, Lawrence
    Weinberg, Vivian
    Chan, Stephen
    Simko, Jeff
    Sims, Robert B.
    Sheikh, Nadeem A.
    Carroll, Peter
    Small, Eric J.
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 740 - 741
  • [48] Optimal MHC-II-restricted tumor antigen presentation to CD4+T helper cells: the key issue for development of anti-tumor vaccines
    Accolla, Roberto S.
    Tosi, Giovanna
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [49] Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer
    Hagihara, Katsunobu
    Chan, Stephen
    Zhang, Li
    Oh, David Y.
    Wei, Xiao X.
    Simko, Jeffry
    Fong, Lawrence
    ONCOIMMUNOLOGY, 2019, 8 (01):
  • [50] Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer
    Crawford, E. David
    Petrylak, Daniel P.
    Higano, Celestia S.
    Kibel, Adam S.
    Kantoff, Philip W.
    Small, Eric J.
    Shore, Neal D.
    Ferrari, Anna
    CANADIAN JOURNAL OF UROLOGY, 2015, 22 (06) : 8048 - 8055